State Street Corp Has $19.03 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

State Street Corp lifted its position in Wave Life Sciences Ltd. (NASDAQ:WVE) by 2.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,321,248 shares of the company’s stock after purchasing an additional 57,822 shares during the quarter. State Street Corp owned 1.86% of Wave Life Sciences worth $19,034,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in Wave Life Sciences by 23.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after buying an additional 856 shares during the last quarter. Profund Advisors LLC acquired a new position in shares of Wave Life Sciences in the 2nd quarter worth approximately $53,000. Principal Financial Group Inc. bought a new stake in Wave Life Sciences during the 2nd quarter worth approximately $74,000. Mackenzie Financial Corp increased its holdings in Wave Life Sciences by 13.6% during the 2nd quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock valued at $79,000 after purchasing an additional 1,905 shares in the last quarter. Finally, Point72 DIFC Ltd bought a new position in Wave Life Sciences in the 3rd quarter valued at $98,000. Institutional investors and hedge funds own 89.73% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on WVE. B. Riley increased their target price on Wave Life Sciences from $19.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Raymond James raised shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $13.00 to $22.00 in a report on Wednesday, October 16th. Truist Financial boosted their target price on shares of Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, November 12th. Leerink Partners increased their price target on shares of Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Finally, Wells Fargo & Company boosted their price objective on shares of Wave Life Sciences from $11.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Wave Life Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $22.22.

Wave Life Sciences Stock Performance

Shares of Wave Life Sciences stock opened at $13.12 on Tuesday. Wave Life Sciences Ltd. has a 52 week low of $3.50 and a 52 week high of $16.74. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -11.82 and a beta of -1.21. The firm has a fifty day moving average of $14.41 and a two-hundred day moving average of $9.07.

Insider Buying and Selling at Wave Life Sciences

In other Wave Life Sciences news, insider Chris Francis sold 36,000 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $576,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Paul Bolno sold 90,474 shares of Wave Life Sciences stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $15.00, for a total transaction of $1,357,110.00. Following the transaction, the chief executive officer now directly owns 268,585 shares in the company, valued at approximately $4,028,775. This represents a 25.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 453,690 shares of company stock valued at $6,425,883. 29.10% of the stock is currently owned by company insiders.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.